Anthracyclines still prove effective in Anticancer Therapy

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 5, 2013, Pages 627-634

  Piekarski, Mikołaj ^a   Jelińska, Anna ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Anthracycline antibiotics; Cancer; Cardiotoxicity; Drugs modifications

Indexed keywords

ACLACINOMYCIN; AMRUBICIN; ANTHRACYCLINE ANTIBIOTIC AGENT; COMBRETASTATIN; DAUNORUBICIN; DIACYLGLYCEROL; DOXORUBICIN; GEMCITABINE; LIPOSOME; MACROGOL; PROTEIN KINASE C; SABARUBICIN; TETRACYCLINE; VALERIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMICAL STRUCTURE; CONGESTIVE HEART FAILURE; DNA STRAND; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG MECHANISM; DRUG STRUCTURE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPOTENSION; LEUKOPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERIZATION; SIDE EFFECT; SKIN MANIFESTATION; STRUCTURE ANALYSIS; VASODILATATION;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; HALF-LIFE; HEART FAILURE; HUMANS; LIPOSOMES; NEOPLASMS;

EID: 84877802471     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313050001     Document Type: Article

References (46)

1. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., Anthracyclines, Molecular Advances an Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol. Rev., 2004, 56, 185-229.
2. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 1999, 57, 727-741.
3. Müller M., Cheneval D., Carafoli E. Doxorubicin inhibits the phosphate-transport protein reconstituted in liposomes. A study on the mechanism if the inhibition. Eur. J. Biochem., 1984, 140, 447-452.
4. Bos A.M., de Vries E.G., Dombernovsky P., Aamdal S., Uges D. R., Schrijvers D., Wanders J., Roelvink M. W., Hanauske A. R., Bortini S., Capriati A., Crea A. E., Vermorken J. B., Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumors. Cancer Chemother Pharmacol., 2001, 48, 361-369.
5. Simunek T., Stérba M., Popelová O., Adamcová M., Hrdina R., Gersl V., Anthracycline-induced cardiotoxicity, Overview of studies examining the roles of oxidative stress and free cellular iron. Pharm. Reports, 2009, 61, 154-171.
6. Mordente A., Meucci E., Silvestrini A., Martorana G.E., Giardina B., New developments in anthracycline-induced cardiotoxicity. Curr. Med. Chem., 2009, 16, 1656-1672.
7. Przybyszewski W.M., Wideł M., Rzeszowska-Wolny J. Kardiotoksyczne nastepstwa promieniowania jonizujacego i antracyklin. Postepy Hig. Med. Dosw., 2006, 60, 397-405.
8. Perez E.A., Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res. Treat, 2009, 114, 195-201.
9. Wasowska M., Wietrzyk J., Opolski A., Oszczapowicz J., Oszczapowicz I., Effect of structural modifications of anthracyclines on the ability to overcome resistance of cancer cells. Anticancer Research, 2006, 26, 2009-2012.
10. Gil J., Stembalska A., Pesz K.A., Sasiadek M.M., Cancer stem cells, the theory and perspectives in cancer therapy. J. App. Genet, 2008, 49(2), 193-199.
11. Baguley B.C., Multiple Drug Resistance Mechanisms in Cancer. Mol. Biotechnol., 2010, 46, 308-316.
12. Fan E., Shi W., Lowary TL. Synthesis of daunorubicin analogues containing truncated aromatic cores and unnatural monosaccharide residues, J Org Chem., 2007, 72, 2917-2928.
13. Gao Y., Priebe W., Wang A. H.-J. Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity. Eur. J. Biochem., 1996, 240, 331-335.
14. Dutta R., Gao Y.G., Priebe W., Wang A.H., Binding of the modified daunorubicin WP401 adjacent to a T-G base pair induces the reverse Watson-Crick conformation, crystal structures of the WP401-TGGCCG and WP401-CGG[br5C]CG complexes. Nucleic Acid Research, 1998, 26, 3001-3005.
15. Tervino A.V. et al. Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues. Mol. Cancer Ther., 2004, 3(11), 1403-1410.
16. Pawłowska J., Tarasiuk J., Borowski E., Wasowska M., Oszczapowicz I., Wolf C.R., The ability of new formamidine sugar-modified derivatives of daunorubicin to stimulate free radical formation in three enzymatic systems, NADH dehydrogenase, NAPDH cytochrome P450 reductase and xanthine oxidase. Acta Biochimica Polonica., 2000, 47, 141-147.
17. Wasowska M., Oszczapowicz I., Wietrzyk J., Opolski A., Madej J., Dzimira S., Oszczapowicz J., Influence of the structure of new anthracycline antibiotics on their biological properties. Anticancer Res., 2005, 25, 2043-2048.
18. Kik K., Studzian K., Wasowska-Łukawska M., Oszczapowicz I., Szmigiero L., Cytotoxicity and inhibitory properties against topoisomerase II of doxorubicin and its formamidine derivatives. Acta Biochimica Polonica, 2009, 56, 135-142.
19. Hofmann P.A., Israel M., Koseki Y., Laskin J., Gray J., Janik A., Sweatman T.W., Lothstein L., N-Benzyladriamycin-14-valerate (AD 198), A Non-Cardiotoxic Anthracycline that is Cardioprotective through PKC-ε Activation. JPET, 2007, 323, 658-664.
20. Roaten J.B., Kazanietz M.G., Caloca M.J., Bertics P.J., Lothstein L., Parrill A.L., Israel M., Sweatman T.W., Interaction of the Novel Anthracycline Antitumor Agent N-Benzyladriamycin-14-valerate with the C1-Regulatory Domain of Protein Kinase C, Structural Requirements, Isoform Specificity, and Correlation with Drug Cytotoxicity. Mol. Cancer Ther., 2002, 1, 483-492.
21. Tevyashova A., Sztaricskai F., Batta G., Herczegh P., Jeney A., Formation of squaric acid amides of anthracycline antibiotics. Synthesis and cytotoxic properties. Bioorg. Med. Chem. Lett., 2004, 14, 4783-4789.
22. Sztaricskai F., Sum A., Roth E., Pelyvás I.F., Sándor S., Batta G., Herczegh P., Reményi J., Miklán Z., Hudecz F., A new class of semisynthetic anthracycline glycoside antibiotics incorporating a squaric acid moiety. J. Antibiot., 2005, 58, 704-714.
23. Yoo B.I., Ahan K.B., Kang M.H., Moon D.C., Kwon O.S., Lee H. S., Ryu J.S., Kim T.Y., Song S., Chung Y.B., HPLC Analysis and Pharmacokinetic Characteristics of 11-Hydroxyaclacinomycin X (ID-6105), a Novel Anthracycline, in Rats and Beagle Dogs. Biol. Pharm. Bull., 2005, 28, 688-693.
24. Case D.C. Jr., Ervin T.J., Boyd M.A., Bove L.G., Sonneborn H.L., Paul S.D., Phase II study of aclarubicin in acute myeloblastic leukemia. Am. J. Clin. Oncol., 1987, 10, 523-526.
25. Mazzini S., Scaglioni L., Animati F., Mondelli R., Interaction between double helix DNA fragments and the new antitumor agent sabarubicin, Men 10755. Bioorg. Med. Chem., 2010, 18, 1497-1506.
26. Sessa C., Valota O., Geroni C. Ongoing phase I and II studies of novel anthracyclines. Cardiovasc. Toxicol., 2007, 7, 75-79.
27. Bressan A., Nardelli F., Bellarosa D., Bigioni M., Curcurù G., Curatella B., Crea A., Maggi C. A., Manzini S., Binaschi M., Sabarubicin (MEN 10755)-induced apoptosis is independent from mtDNA in A2780 human ovarian tumor cells. Anticancer Res., 2007, 27, 4039-4046.
28. Gonzalez-Paz O., Polizzi D., De Cesare M., Zunino F., Bigioni M., Maggi C. A., Manzini S., Pratesi G., Tissue distribution, antitumor activity and in vivo apoptosis induction by MEN10755 in nude mice. Eur. J. Cancer, 2001, 37, 431-437.
29. Zhu L., Cao X., Chen W., Zhang G., Sun D., Wang P.G., Syntheses and biological activities of daunorubicin analogs with uncommon sugars. Bioorg. Med. Chem. 2005, 13, 6381-6387.
30. Animati F., Arcamone F., Berettoni M., Cipollone A., Franciotti M., Lombardi P., New anthracyclines disaccharides synthesis of L-daunosaminyl-α(1→4)-2-deoxy-L-rhamnosyl and of L-daunosaminyl-α(1→4)-2-deoxy-L-fucosyl daunorubicin analogues, J Chem Soc Perkin Trans, 1996, 12, 1327-1329.
31. Kurata T., Okamoto I., Tamura K., Fukuoka M., Amrubicin for non-small-cell lung cancer and small-cell lung cancer. Invest New Drugs, 2007, 25, 499-504.
32. Ettinger D. S., Amrubicin for the Treatment of Small Cell Lung Cancer, Does Effectiveness Cross the Pacific?. J. Thorac. Oncol., 2007, 2, 160-165.
33. Ettinger D.S., Jotte R., Lorigan P., Gupta V., Garbo L., Alemany C., Conkling P, Spigel D. R., Dudek A.Z., Shah Ch., Salgia R., McNally R., Renschler M.F., Oliver J.W., Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer. J. Clin. Oncol., 2010, 28, 2598-2603.
34. Carvalho H., Garrido L.M., Furlan R.L., Padilla G., Agnoletto M., Guecheva T., Henriques J. A., Saffi J., Menck C. F., DNA damage induced by the anthracycline cosmomycin D in DNA repair-deficient cells. Cancer Chemother Pharmacol., 2010, 65, 989-994.
35. Cirili M., Bachechi F., Ughetto G., Colonna F. P., Capobianco M. L., Interactions between morpholinyl anthracyclines and DNA. J. Mol. Biol., 1993, 230, 878-889.
36. Nadas J., Sun D. Anthracyclines as effective anticancer agents, Expert Opin Drug Discov. 2006, 1, 539-548.
37. Zucchi R., Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr. Med. Chem. Anticancer Agents, 2003, 3, 151-171.
38. Huober J., Fett W., Nusch A., Neise M., Schmidt M., Wischnik A., Gerhardt S., Goehler T., Lück H. J., Rost A., A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer, 2010, 10, 2.
39. Adamo V., Lorusso V., Rossello R., Adamo B., Ferraro G., Lorusso D., Condemi G., Priolo D., Di Lullo L., Paglia A., Pisconti S., Scambia G., Ferrandina G., Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer, a multicentre phase II study. Br. J. Cancer, 2008, 98, 1916-1921.
40. Chang D.K., Lin C.T., Wu C.H., Wu H.C., A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung Cancer. PLoS ONE, 2009, 4, 4171.
41. Cheng C., Haouala A., Krueger T., Mithieux F., Perentes J.Y., Peters S., Decosterd L.A., Ris H.B., Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin. Interactive Cardio Vascular and Thoracic Surgery, 2009, 8, 635-638.
42. Mitrus I., Sochanik A., Cichoń T., Szala S., Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochimica Polonica, 2009, 56, 161-165.
43. Veronese F. M., Schiavon O., Pasut G., Mendichi R., Andersson L., Tsirk A., Ford, Wu G., Kneller S., Davies J., Duncan R., PEG-doxorubicin conjugates, influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem., 2005, 16, 775-784.
44. DiPaola R.S., Rinehart J., Nemunaitis J., Ebbinghaus S., Rubin E., Capanna T., Ciardella M., Doyle-Lindrud S., Goodwin S., Fontaine M., Adams N., Williams A., Schwartz M., Winchell G., Wickersham K., Deutsch P., Yao S. L., Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J. Cin. Oncol., 2002, 20, 1874-1879.
45. Gibbs D.D., Pyle L., Allen M., Vaughan M., Webb A., Johnston S. R., Gore M. E., A phase I dose-finding study of combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br. J. Cancer, 2002, 86, 1379-1384.
46. Mavroudis D., Kouroussis Ch., Kakolyris S., Agelaki S., Kalbakis K., Androulakis N., Souglakos J., Samonis G., Georgoulias V., Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administrated every 2 weeks in patients with advanced solid tumors, Oncology, 2002, 62, 216-222.